Company intelligence / Profile preview

Sironax

Ownership: Private
Development stage: Phase 1

Overview

Sironax has multiple programs in clinical development, with SIR1-365 in Phase 1/2 for COVID-19, SIR2501 in Phase 1 for ALS, SIR9900 in Phase 1 for neurodegenerative diseases, and SIR-2446M with IND approval for multiple sclerosis. The company focuses on mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation.

Therapeutic areas: ImmunologyCardiovascularNeurologyInfectious Diseases
Modalities: Small molecule drugsChemical drugs
Industry: Biotech

Drug pipeline

12 assets

SIR2501

11 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sironax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sironax.

Explore the full profile